Effectiveness and Safety of Regorafenib and TAS-102 in Patients with Metastatic Colorectal Cancer: A Nationwide Population-Based Study in Taiwan.

Cancer Res Treat · 2025 · PMC12263230 · PMID 39563201

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The REGOTAS study showed a trend that regorafenib was preferred for patients < 65 years while TAS-102 was favorable among those aged ≥ 65 years [ 14 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.